rs766485358
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 1P and 9B. PP2BP4_StrongBS1_SupportingBS2
The NM_005120.3(MED12):c.1682C>T(p.Pro561Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000298 in 1,206,807 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 11 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_005120.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000358 AC: 4AN: 111587Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33757
GnomAD3 exomes AF: 0.0000228 AC: 4AN: 175798Hom.: 0 AF XY: 0.0000161 AC XY: 1AN XY: 62010
GnomAD4 exome AF: 0.0000292 AC: 32AN: 1095220Hom.: 0 Cov.: 31 AF XY: 0.0000305 AC XY: 11AN XY: 360680
GnomAD4 genome AF: 0.0000358 AC: 4AN: 111587Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33757
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 16, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Feb 07, 2017 | The P561L variant in the MED12 gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The P561L variant is observed in 1/5278 (0.019%) alleles from individuals of East Asian background, including one hemizygous individual, in the ExAC dataset (Lek et al., 2016. The P561L variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved in mammals. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. We interpret P561L as a variant of uncertain significance. - |
Familial thoracic aortic aneurysm and aortic dissection Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 06, 2024 | The c.1682C>T (p.P561L) alteration is located in exon 12 (coding exon 12) of the MED12 gene. This alteration results from a C to T substitution at nucleotide position 1682, causing the proline (P) at amino acid position 561 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
FG syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 13, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at